Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial

Given commonly employed thresholds in the UK NHS, on balance co-trimoxazole may be a cost-effective treatment for IPF, although there is substantial decision uncertainty. However, recent guidance on the use of immunosuppressive therapy in IPF patients should be taken into account prior to any policy decision. </AbstractSection> Copyright Springer International Publishing Switzerland 2014

MoreLess

Year of publication:	2014
Authors:	Wilson, Edward ; Shulgina, Ludmila ; Cahn, Anthony ; Chilvers, Edwin ; Parfrey, Helen ; Clark, Allan ; Twentyman, Orion ; Wilson, Andrew
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 32.2014, 1, p. 87-99
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001781